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ABSTRACT
Objectives: There is increasing evidence that passive
smoking is associated with chronic respiratory
diseases, but its association with chronic obstructive
pulmonary disease (COPD) requires more study. In
this cross-sectional analysis of data from 3 years of
the Health Survey for England, the association between
passive smoking exposure and risk of COPD is
evaluated.
Design: Cross-sectional analysis of the 1995, 1996
and 2001 Health Surveys for England including
participants of white ethnicity, aged 40+ years with
valid lung function data. COPD was deﬁned using the
lower limit of normal spirometric criteria for airﬂow
obstruction. Standardised questions elicited self-
reported information on demography, smoking history,
ethnicity, occupation, asthma and respiratory
symptoms (dyspnoea, chronic cough, chronic phlegm,
wheeze). Passive smoking was measured by self-
report of hours of exposure to cigarette smoke per
week.
Results: Increasing passive smoke exposure was
independently associated with increased risk of COPD,
with adjusted OR 1.05 (95% CI 0.93 to 1.18) for
1e19 h and OR 1.18 (95% CI 1.01 to 1.39) for 20 or
more hours of exposure per week. Similar patterns
(although attenuated and non-signiﬁcant) were
observed among never smokers. More marked
doseeresponse relationships were observed between
passive smoking exposure and respiratory symptoms,
but the most marked effects were on the development
of clinically signiﬁcant COPD (airﬂow obstruction plus
symptoms), where the risk among never smokers was
doubled (OR 1.98 (95% CI 1.03 to 3.79)) if exposure
exceeded 20 h/week.
Conclusion: This analysis adds weight to the evidence
suggesting an association between passive smoking
exposure and COPD.
INTRODUCTION
Active smoking is accepted as the most
important risk factor for the development of
chronic obstructive pulmonary disease
(COPD), and is responsible for over 70% of
cases in high income countries, although far
fewer (w40%) in lower income countries.
1
The remaining risk is attributed to a number
of environmental factors, including occupa-
tional exposure to dust and fumes, and
indoor and outdoor air pollution.
2
Passive exposure to cigarette smoke is
accepted as an independent risk factor for
heart disease and lung cancer,
3 4 and has also
been implicated in the aetiology of COPD,
25
although the association between passive
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ARTICLE SUMMARY
Article focus
- Passive exposure to cigarette smoke is estab-
lished as an important independent risk factor for
the development of chronic conditions such as
heart disease and lung cancer.
- Although there is growing evidence implicating
passive smoking in asthma and other respiratory
diseases, the evidence for its effect on chronic
obstructive pulmonary disease (COPD) is incon-
sistent.
- Using cross-sectional data from the annual
Health Survey for England, we examined the
association between self-reported exposure to
passive smoking and COPD.
Key messages
- We have demonstrated a signiﬁcant
doseeresponse relationship between hours of
exposure to passive smoking and increasing risk
of COPD.
- The most marked effects were observed on the
development of clinically signiﬁcant COPD
(airﬂow obstruction plus symptoms), where the
risk among never smokers was doubled (OR 1.98
(95% CI 1.03 to 3.79)) if exposure exceeded
20 h/week.
- Passive smoking is prevalent worldwide, and
even after the 2007 public smoking ban in the
UK, 20% of the adult English population are still
exposed to up to 20 h of passive smoking per
week, with 5% exposed to more than 20 h/week;
further measures are needed to investigate and
reduce exposures in the home and elsewhere.
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Open Access Researchsmoking and COPD is less well deﬁned. There is
increasing evidence that passive smoking is an important
risk factor in chronic respiratory diseases. A number of
studies suggest that asthma can be induced by exposure
to passive smoking,
6 and there is strong evidence to
suggest that passive smoking increases the risk of general
respiratory symptoms.
6e11 Many previous studies have
also examined the relationship between passive smoking
and lung function, but with inconsistent results.
6
Evidence is now emerging that COPD may be indepen-
dently associated with passive smoking exposure,
71 1 e18
although a recent editorial
19 highlighted that more
studies were required before a causal role could be
established.
One difﬁculty with evaluating such an association is
the number of subjects required to demonstrate the
relatively small RRs associated with passive smoking risks
(in the region of 1.2e1.5).
12 13 The Health Survey for
England (HSE) has the advantage of size (over 15000
adults are surveyed every year), generalisability and
a standard protocol which is repeated annually. In 1995,
1996 and 2001, lung function was measured, providing
the opportunity to examine the association between
passive smoking and COPD in large numbers of people.
The large size also allows the analysis to be restricted to
never smokers, thus reducing any misclassiﬁcation of
reported exposure to passive smoking which could occur
among smokers.
METHODS
Study design
Cross-sectional analysis of data collected by the annual
HSE in 1995, 1996 and 2001, was carried out to establish
the association between passive smoking and COPD.
Setting
The HSE is part of a set of annual surveys designed to
monitor population health. The dataset is publicly
available and obtained from the UK Data archive.
20
Brieﬂy, an independent general population sample was
surveyed each year obtained by multistage stratiﬁed
random sampling of private households in
England.
21e23 Postcode sectors were sorted by health
authority and, within each health authority by the
percentage of households where the head of the
household had a non-manual occupation. A total of 720
postcode sectors were selected, with the probability of
selection proportional to the number of delivery points
(or addresses) in each sector. Nineteen addresses were
selected from each sector. (Selecting sectors and
addresses in this way ensures each household has an
equal probability of selection.) Up to three households
could be selected in any one postcode address. Home
interviews and health assessments by trained interviewers
and nurses were carried out for over 15000 different
adults each year. In 1995, 1996 and 2001, an assessment
of lung function (FEV1, FVC and PEF) was included, and
in 1995 and 1996, information on respiratory health was
additionally collected. Data from all 3 years were
combined with adjustment for year of study in the
analyses.
Participants
Participants of white ethnicity, aged 40 years and above
and with valid lung function tests and height data were
included in the analysis. Because only pre-bronchodi-
lator spirometry was available, participants reporting
a diagnosis of asthma were excluded from the main
analyses but included in sensitivity analyses. Analyses
were carried out among all participants and separately
among never smokers.
Questionnaire and procedures
All consenting participants within the HSE were
administered a detailed standardised computer-assisted
interview used in previous survey years and seeking
information on demographic characteristics, smoking
history, ethnicity, occupation and educational level.
Socioeconomic status was grouped into non-manual
occupations and manual/other occupations. Partici-
pants were speciﬁcally asked if they had ever been
diagnosed with asthma and whether they experienced
a range of respiratory symptoms. Standard questions
about wheeze, dyspnoea, chronic cough and chronic
phlegm were included:
Wheeze: yes to either of:
Have you had wheezing or whistling in the chest in the
last 12 months?
In the past 12 months, have you been woken by an attack
of shortness of breath?
Dyspnoea: yes to any of:
Are you troubled by shortness of breath when hurrying
on level ground or walking up a slight hill?
Do you get short of breath walking with other people of
your own age on level ground?
Do you have to stop for breath when walking at your own
pace on level ground?
Chronic cough: yes to either of the ﬁrst two and yes to
3 months of coughing
Do you usually cough ﬁrst thing in the morning in
winter?
ARTICLE SUMMARY
Strengths and limitations of this study
- Our study has the advantage of being a large sample
representative of the English population (>21000 partici-
pants), conducted over 3 separate years, with a standardised
protocol and objective measure of lung function.
- However, due to the cross-sectional nature of the design,
temporal associations cannot necessarily be inferred.
- The Health Survey for England was not designed for the
speciﬁc analyses presented in this paper, and thus some of the
measures are crude.
- Self-reported passive smoke exposure is only a proxy for true
exposure levels, but is accepted as the most practical method
of assessment.
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Passive smoking and COPDDo you usually cough during the day or at night in the
winter?
Do you cough like this on most days for as much as
3 months each year?
Chronic phlegm: yes to either of the ﬁrst two and yes
to 3 months of phlegm
Do you usually bring up any phlegm from your chest,
ﬁrst thing in the morning in winter?
Do you usually bring up any phlegm from your chest,
during the day or at night in the winter?
Do you bring up phlegm like this on most days for as
much as 3 months each year?
Smoking habit was deﬁned as current, ex- and never
regular smokers (where regular was deﬁned as at least
one cigarette per day). Passive smoking exposure was
measured by self-report of the number of hours
currently exposed to cigarette smoke per week: “Now, in
most weeks, how many hours a week are you exposed to
other people’s tobacco smoke?” As there was no lifetime
indicator of chronic passive smoking exposure, this was
assumed to be indicative of past adult exposure, aided by
the data being collected before the 2007 public smoking
ban in England.
Among other measurements, pulmonary function
tests, without reversibility, were performed according to
a standard protocol
18e20 with a Vitalograph (Maids
Moreton, Buckinghamshire, UK) Escort spirometer
(Fleisch pneumotachograph ﬂow head) which was
Table 1 Characteristics of included and excluded participants
Included participants Excluded
participants* 1995 1996 2001 Total
n 7071 7565 6468 21104 6549
Males 3303 (46.7%) 3551 (46.9%) 2993 (46.3%) 9847 (46.7%) 2616 (40.0%)
Mean age, years (SD) 58.4 (12.3) 58.1 (12.3) 57.9 (11.9) 58.1 (12.2) 63.9 (14.3)
Age group
40e49 2129 (30.1%) 2409 (31.8%) 1872 (28.9%) 6410 (30.4%) 1389 (21.2%)
50e59 1812 (25.6%) 1876 (24.8%) 1954 (30.2%) 5642 (26.7%) 1290 (19.7%)
60e69 1598 (22.6%) 1695 (22.4%) 1380 (21.3%) 4673 (22.1%) 1317 (20.1%)
70e79 1158 (16.4%) 1186 (15.7%) 969 (15.0%) 3313 (15.7%) 1418 (21.7%)
80+ 374 (5.3%) 399 (5.3%) 293 (4.5%) 1066 (5.1%) 1135 (17.3%)
Socioeconomic statusy
Non-manual occupations 3928 (56.4%) 4195 (56.2%) 3683 (57.8%) 11806 (56.7%) 3117 (49.6%)
Manual occupations 3028 (43.4%) 3254 (43.6%) 2676 (42.0%) 8958 (43.1%) 3158 (50.2%)
Other 14 (0.2%) 17 (0.2%) 13 (0.2%) 44 (0.2%) 13 (0.2%)
Smoking statusy
Current 1612 (22.8%) 1806 (23.9%) 1327 (20.5%) 4745 (22.5%) 1536 (23.5%)
Ex-regular 2569 (36.4%) 2637 (34.9%) 2290 (35.4%) 7496 (35.5%) 2237 (34.2%)
Never regular 2887 (40.9%) 3122 (41.3%) 2850 (44.1%) 8859 (42.0%) 2775 (42.4%)
Pack years smoked
0 3107 (44.0%) 3359 (44.4%) 3038 (47.0%) 9504 (45.0%) 2973 (45.4%)
1e19 1817 (25.7%) 1922 (25.4%) 1656 (25.6%) 5395 (25.6%) 1517 (23.2%)
20e49 1695 (24.0%) 1803 (23.8%) 1389 (21.5%) 4887 (23.2%) 1552 (23.7%)
50+ 449 (6.4%) 481 (6.4%) 384 (5.9%) 1314 (6.2%) 506 (7.7%)
Exposure to passive smoking, h
Mean hours per week (SD) 9.2 (18.4) 9.3 (18.3) 6.1 (13.8) 8.3 (17.1) 7.0 (16.3)
Median hours per week
(IQR)
2( 0 e8) 2 (0e8) 1 (0e5) 1 (0e7) 0 (0e5)
0 2859 (40.5%) 3111 (41.2%) 3167 (49.1%) 9137 (43.4%) 3425 (52.6%)
1e9 2540 (36.0%) 2665 (35.3%) 2193 (34.0%) 7398 (35.1%) 1883 (28.9%)
10e19 667 (7.9%) 560 (7.4%) 440 (6.8%) 1557 (7.4%) 425 (6.5%)
20+ 1105 (15.7%) 1224 (16.2%) 657 (10.2%) 2986 (14.2%) 778 (12.0%)
Any respiratory symptomsz 3120 (44.1%) 3340 (44.2%) e 6460 (44.1%) 1823 (47.7%)
Physician-diagnosed asthma 692 (9.8%) 794 (10.5%) 801 (12.4%) 2287 (10.8%) 702 (10.7%)
COPDx
LLN 675 (10.6%) 593 (8.8%) 414 (7.3%) 1682 (8.9%) e
GOLD 1190 (18.7%) 1086 (16.1%) 757 (13.4%) 3033 (16.1%) e
NICE 526 (8.3%) 443 (6.6%) 333 (5.9%) 1302 (6.9%) e
*Excluded due to invalid lung function or height measurements.
yMissing data: 557/27653 (2.0%) had missing socioeconomic status and 5/27653 (0.02%) missing smoking history.
zDyspnoea, wheeze, chronic cough or phlegm. Not recorded in 2001.
xAmong those without asthma: GOLD criteria
26: FEV1/FVC ratio <0.7; NICE criteria: FEV1/FVC<0.7 and FEV1<80% predicted (equivalent to
GOLD stage II)
27; lower limit of normal (LLN) criteria
24 25: participants with FEV1/FVC values >1.645 SD below the mean reference value.
COPD, chronic obstructive pulmonary disease.
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Passive smoking and COPDcalibrated daily at normal room temperature. The best
FEV1 and FVC measurements were used.
Outcomes
T h em a i no u t c o m em e a s u r ew a st h ep r e s e n c eo fC O P D ,
deﬁned by using the reference equations from the
European Community for Steel and Coal Study
24 and
t h el o w e rl i m i to fn o r mal (LLN) criterion.
25 In this way,
participants were classiﬁed as having obstructive airways
disease if their pre-bronchodilator FEV1/FVC values
were below the lowest 5% of the frequency distribution
of values found in the healthy reference population.
Secondary outcome measures were the presence of any
chronic respiratory symptoms (wheeze, dyspnoea,
chronic cough, chronic phlegm, as detailed above)
and the presence of clinically signiﬁcant COPD
(both airﬂow obstruction (LLN) and any of the above
respiratory symptoms). Analyses were repeated using
both pre-bronchodilator modiﬁed GOLD
26 (FEV1/
FVC ratio<0.7) and NICE criteria
27 (FEV1/FVC<0.7
and FEV1<80% predicted, equivalent to GOLD stage
II). Because lung function data were pre-bronchodi-
lator, some patients with airﬂow obstruction could
have asthma rather than COPD. The analyses were
initially undertaken excluding participants with
asthma and then repeated including participants with
asthma.
Statistical analysis
Univariate and multivariate logistic regression were
undertaken in STATA V.10.0, in the latter adjusting for
age, sex, smoking history, year of study, socioeconomic
status and self-reported asthma where appropriate and
adding signiﬁcantly to the statistical model.
RESULTS
Study participants
Of 27653 white adults aged 40 years and older, 6549
(23.7%) were excluded because they did not have valid
lung function data or a reliable height measurement.
Table 1 describes the baseline characteristics of the
remaining included participants, by year and compared
with the excluded participants. The mean age of the
participants was 58.1 years (SD 12.2) and 9847 (46.7%)
were male. Age and sex distributions were similar for
each year. Overall, 4745 (22.5%) were current smokers
and 8859 (42.0%) had never smoked regularly; there
were fewer current and more never smokers in 2001
compared with previous years. Most smokers had
smoked less than 50 pack-years.
Exposure to passive smoking declined over time, with
2859 (40.5%) experiencing no exposure in 1995, which
increased to 3167 (49.1%) by 2001. Numbers exposed in
the highest exposure group (20 or more hours per
week) dropped from 1105 (15.7%) in 1995 to 657
(10.2%) in 2001.
COPD prevalence among participants without asthma
(LLN criteria) also decreased from 10.6% in 1995 to
7.3% in 2001. COPD measured by modiﬁed GOLD or
NICE criteria showed similar patterns, although absolute
prevalence values differed by deﬁnition.
Excluded participants (table 1) were more likely to be
older, female, have manual occupations and greater
respiratory symptoms but lower current exposure to
passive smoking.
Association between passive smoking and COPD
For each of the 3 years, risk of COPD increased with
increasing age and was highest among current smokers
compared with never regular smokers, and manual
workers compared with non-manual workers (table 2).
Females had a lower risk (OR 0.87 (95% CI 0.78 to 0.97)
for combined data). Exposure to passive smoking was
associated with increased risk of COPD, although for
individual years this effect was not statistically signiﬁcant.
For the combined data, increasing exposure to passive
cigarette smoke was independently associated with
increased risk of COPD, with OR 1.05 (95% CI 0.93 to
1.18) for up to 20 h and OR 1.18 (1.01 to 1.39) for 20 or
more hours of exposure per week once year of study and
socioeconomic status were taken into account.
Restricting the analyses to never regular smokers
resulted in similar patterns, but with a lower sample size
(n¼7789) the risk estimates became non-signiﬁcant (OR
Table 3 Association between passive smoking and
respiratory symptoms and clinically signiﬁcant chronic
obstructive pulmonary disease among never-smoking
participants of the Health Survey for England, 1995/1996
Respiratory
symptoms*
Clinically signiﬁcant
COPDy
Adjusted ORz
(95% CI)
Adjusted ORz
(95% CI)
n 5441 5441
Age (years)
40e49 1.00 1.00
50e59 1.37 (1.16 to 1.62) 1.46 (0.74 to 2.87)
60e69 2.03 (1.72 to 2.40) 2.73 (1.46 to 5.10)
70e79 3.06 (2.54 to 3.68) 6.33 (3.48 to 11.54)
80+ 4.22 (3.29 to 5.40) 11.08 (5.76 to 21.30)
Sex
Male 1.00 1.00
Female 1.32 (1.17 to 1.50) 0.99 (0.67 to 1.44)
Year
1995 1.00 1.00
1996 0.97 (0.87 to 1.09) 0.61 (0.42 to 0.87)
Passive smoking exposure (h/week)
0 1.00 1.00
1e19 1.20 (1.06 to 1.37) 1.52 (1.04 to 2.23)
20+ 1.68 (1.36 to 2.08) 1.98 (1.03 to 3.79)
*Respiratory symptoms: any of dyspnoea, wheeze, chronic cough
or phlegm.
yLower limit of normal (LLN) criteria
24 25: participants with FEV1/
FVC values >1.645 SD below the mean reference value plus
respiratory symptoms.
zAdjusted for age, sex, passive smoking exposure and year of
study.
COPD, chronic obstructive pulmonary disease.
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Passive smoking and COPD1.14 (0.91 to 1.42) and 1.17 (0.78 to 1.76) for 1e19 and
$20 h of exposure, respectively).
Effect of passive smoking on respiratory symptoms
The effect of passive smoking exposure on respiratory
symptoms is shown in table 3 (data from 1995 and 1996).
Never-smoking participants with increasing exposure to
passive smoking were at increased risk of reporting
respiratory symptoms, with OR 1.20 (1.06 to 1.37) for
exposure levels of 1e19 h/week and OR 1.68 (1.36 to
2.08) for $20 h of exposure. Notably, there was a signif-
icantly increased risk among females compared with
males of reporting any respiratory symptoms (OR 1.32
(1.17 to 1.50)).
Furthermore, the risk of clinically signiﬁcant COPD
(ie, having both respiratory symptoms and evidence of
airﬂow obstruction by spirometry) among never-smoking
participants exposed to passive smoking was higher than
the risk of symptoms alone (OR 1.52 (1.04 to 2.23) for
1e19 h and 1.98 (1.03 to 3.79) for $20 h/week of
exposure).
Sensitivity analyses
Repeating the analyses with alternative spirometric
criteria for COPD showed similar patterns (table 4).
However, males and those who were older showed
increased independent risks of COPD with both these
deﬁnitions. Inclusion of participants reporting asthma
(table 5) led to similar patterns of the effect of passive
smoking on COPD and respiratory symptoms, although
sometimes loss of signiﬁcance for the two outcomes
which included airﬂow obstruction.
DISCUSSION
In this population-based analysis of over 21000 subjects,
an independent doseeresponse relationship between
exposure to passive smoking and chronic respiratory
disease was observed. Results were not always statistically
signiﬁcant, but the effect was consistently present in
each year of the survey, with different spirometric deﬁ-
nitions of COPD, with and without respiratory symp-
toms, with respiratory symptoms alone, and among
never smokers as well as the total population. The effect
of passive smoking exposure was most marked among
never smokers having clinically signiﬁcant COPD, where
never smokers exposed to between 1 and 19 h of passive
smoking had a 52% excess risk and those exposed to
$20 h had an excess risk of 98%.
Passive smoking was associated with higher risks of
reporting respiratory symptoms (OR 1.68 (1.36 to 2.08))
among never smokers, which is consistent with other
European studies,
7 81 1although not with a large study in
China.
12 However, it has been shown that symptoms are
consistently less likely to be reported in South-East Asia
than in Europe.
28 More women also reported respiratory
symptoms, which is similar to ﬁndings elsewhere.
7
It is difﬁcult to compare the results for COPD with
other studies as deﬁnitions for COPD differ, as do
Table 4 Association between passive smoking and chronic obstructive pulmonary disease among never-smoking participants
of the Health Survey for England: effect of alternative spirometric deﬁnitions
GOLD criteria* NICE criteria*
COPD
Clinically signiﬁcant
COPDy COPD
Clinically signiﬁcant
COPDy
Adjusted
OR (95% CI)z
Adjusted
OR (95% CI)z
Adjusted
OR (95% CI)z
Adjusted
OR (95% CI)z
n 7944 5443 7944 5443
Age (years)
40e49 1.00 1.00 1.00 1.00
50e59 1.69 (1.32 to 2.16) 2.17 (1.27 to 3.71) 1.85 (1.00 to 3.44) 3.92 (1.06 to 14.53)
60e69 2.75 (2.17 to 3.49) 4.14 (2.50 to 6.85) 5.13 (2.96 to 8.91) 11.26 (3.33 to 38.05)
70e79 4.48 (3.51 to 5.72) 8.87 (5.40 to 14.58) 10.95 (6.35 to 18.86) 29.68 (8.96 to 98.30)
80+ 9.00 (6.80 to 11.92) 21.81 (12.91 to 36.83) 18.42 (10.28 to 33.03) 60.77 (17.83 to 207.18)
Sex
Male 1.00 1.00 1.00 1.00
Female 0.56 (0.48 to 0.66) 0.62 (0.48 to 0.82) 0.53 (0.40 to 0.70) 0.45 (0.29 to 0.69)
Year
1995 1.00 1.00 1.00 1.00
1996 0.76 (0.64 to 0.90) 0.68 (0.52 to 0.88) 0.61 (0.44 to 0.84) 0.57 (0.37 to 0.88)
2001 0.67 (0.55 to 0.80) e 0.61 (0.43 to 0.86) e
Passive smoking exposure (h/week)
0 1.00 1.00 1.00 1.00
1e19 1.11 (0.94 to 1.31) 1.31 (0.98 to 1.74) 1.10 (0.81 to 1.49) 1.09 (0.68 to 1.74)
20+ 1.10 (0.81 to 1.49) 1.82 (1.12 to 2.97) 1.33 (0.74 to 2.38) 1.92 (0.88 to 4.23)
*GOLD criteria
26: FEV1/FVC ratio <0.7; NICE criteria: FEV1/FVC<0.7 and FEV1<80% predicted (equivalent to GOLD stage II).
27
yParticipants with airﬂow obstruction plus respiratory symptoms (any of dyspnoea, wheeze, chronic cough or phlegm).
zAdjusted for age, sex, passive smoking exposure and year of study.
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Passive smoking and COPDpassive smoking exposure measures. However, previous
studies
7 12e14 16e18 have indicated signiﬁcant increased
risk of COPD with increasing passive smoking exposure,
with ORs between 1.31 and 2.24, depending on the
deﬁnitions used and the study design. In China,
12 being
exposed to $40 h of passive smoking per week for at least
5 years was associated with risks of spirometrically deﬁned
COPD among never smokers of 1.48 (1.18 to 1.85).
Similarly, in Estonia, for those with more than 5 h of
passive smoking exposure per day outside the home (ie,
more than 35 h/week), the risk of physician-diagnosed
chronic bronchitis or emphysema was 1.54 (1.13 to 3.00).
7
For those with 1e5 h/day (7e35 h/week), the risk was
lower (OR 1.16 (0.88 to 1.53)). Passive smoking exposure
is lower in England, and likely to have reduced further,
subsequent to the collection of our data, since smoking in
public places was banned in 2007. Nevertheless, we found
that among never smokers with $20 h of exposure, there
was a risk of 1.17 (0.78 to 1.76) for spirometrically deﬁned
COPD, which was between one-third and one-half of the
excess risk observed in China or Estonia for approxi-
mately half of the reported exposure.
However, risks were highest for never smokers with
clinically signiﬁcant COPD (OR 1.98 (1.03 to 3.79) for
$20 h of exposure). The greater risks are likely to reﬂect
tighter disease deﬁnitions (and more severe disease) and
less disease and exposure misclassiﬁcation. The effects of
passive smoking exposure seen with alternative deﬁni-
tions of COPD are similar, although lack of statistical
signiﬁcance and more extreme effects of age and sex are
likely to reﬂect less accurate disease deﬁnitions. In
particular, our results highlight the known age and sex
bias inherent in the GOLD and NICE criteria for
COPD.
29
Nevertheless, our calculated risks all fall within the
range reported in previous studies, and indicate that our
analysis reﬂects, and adds to, the weight of previous
evidence. Our results also accord with published excess
risks of passive smoking for heart disease, lung cancer
and asthma.
3 46
Strengths and limitations
Our study has the advantage of being a large sample
representative of the English population, conducted over
3 separate years, with a standardised protocol and objec-
tive measure of lung function. There were over 21000
participants, including 8859 never smokers. In addition,
we initially excluded those with physician-diagnosed
asthma, as some studies have suggested that the effect of
passive smoking on lung function is conﬁned to those
with increased susceptibility such as asthma,
30e32 and in
order to reduce misclassiﬁcation of COPD. Our sensitivity
analyses demonstrated that the effects show a consistent
pattern among those with and without asthma.
However, due to the cross-sectional nature of the
design, temporal associations cannot be inferred and it is
Table 5 Association between passive smoking, COPD, respiratory symptoms and clinically signiﬁcant COPD among
never-smoking participants of the Health Survey for England (data including participants reporting presence of asthma)
COPD* Respiratory symptomsy Clinically signiﬁcant COPDz
Adjusted OR (95% CI)x Adjusted OR (95% CI)x Adjusted OR (95% CI)x
n 8849 6004 6004
Age (years)
40e49 1.00 1.00 1.00
50e59 1.06 (0.82 to 1.35) 1.33 (1.14 to 1.56) 1.17 (0.75 to 1.82)
60e69 1.30 (1.02 to 1.67) 2.04 (1.74 to 2.39) 2.13 (1.41 to 3.22)
70e79 1.88 (1.45 to 2.46) 2.93 (2.45 to 3.50) 3.59 (2.35 to 5.49)
80+ 2.98 (2.16 to 4.13) 3.90 (3.06 to 4.96) 5.54 (3.31 to 9.28)
Sex
Male 1.00 1.00 1.00
Female 0.93 (0.78 to 1.12) 1.38 (1.22 to 1.56) 0.96 (0.71 to 1.28)
Asthma
No 1.00 1.00 1.00
Yes 4.51 (3.70 to 5.50) 7.17 (5.85 to 8.80) 10.20 (7.65 to 13.59)
Year
1995 1.00 1.00 1.00
1996 0.81 (0.66 to 0.98) 0.99 (0.88 to 1.10) 0.71 (0.54 to 0.94)
2001 0.64 (0.52 to 0.80) ee
Passive smoking exposure (h/week)
0 1.00 1.00 1.00
1e19 1.16 (0.97 to 1.40) 1.19 (1.05 to 1.34) 1.19 (0.88 to 1.61)
20+ 1.25 (0.90 to 1.72) 1.70 (1.39 to 2.08) 1.47 (0.89 to 2.43)
*Lower limit of normal (LLN) criteria
24 25: participants with FEV1/FVC values >1.645 SD below the mean reference value.
yRespiratory symptoms: any of dyspnoea, wheeze, chronic cough or phlegm.
zLower limit of normal (LLN) criteria
24 25: participants with FEV1/FVC values >1.645 SD below the mean reference value plus respiratory
symptoms.
xAdjusted for age, sex, passive smoking exposure, year of study and history of asthma.
COPD, chronic obstructive pulmonary disease.
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Passive smoking and COPDpossible that participants with either respiratory symp-
toms, poorer lung function or a respiratory diagnosis
may have modiﬁed their exposure to passive smoking.
Nonetheless, this would be most likely to manifest in
a reduction of their exposure and thus have the effect of
underestimating any positive associations between
passive smoking exposure and COPD. Additionally, the
HSE was not designed for the speciﬁc analyses presented
in this paper, and thus some of the measures are crude.
We used self-reported current passive exposure status,
assuming that this would reﬂect past exposure, although
this may have changed over time. In general, passive
smoking exposure reduced between 1995 and 2001, and
if past exposures were greater, then our analysis may
have overestimated the effects at a given exposure level.
Also, self-reported exposure is only a proxy for true
exposure levels but is accepted as the most practical
method of assessment. In addition, the spirometry, while
undertaken to a standardised protocol, may not have
reached currently recommended quality criteria
25 and
could have misclassiﬁed some participants.
Recall bias of passive smoking exposure would not be
likely as this is a large survey with many questions and no
particular hypothesis associated with respiratory disease.
It is also possible that the observed effects of passive
smoking in our analysis may be partly attributable to
residual confounding, as any effects of indoor air
pollution or occupational exposure could not be
accounted for.
In summary, our study, although cross-sectional, lends
weight to the argument that passive smoking is an
important modiﬁable risk factor for COPD, and is
consistent with other published evidence. In the UK
(and many other western countries), passive smoking
outside the home has been reducing, although, even
after the public smoking ban, 20% of the adult English
population are still exposed to up to 20 h of passive
smoking per week, and 5% to more than 20 h/week
(unpublished analysis of HSE 2007).
33 Further investi-
gation is required to determine whether subgroups of
the population are experiencing greater exposure in the
home since the smoking ban, and what strategies might
be effective in reducing their exposure. However, in
developing countries, passive smoking is still a major
problem in the workplace and policy makers should
strive to reduce this.
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